In a report released on March 30, Nicolas Pauillac from Kepler Capital maintained a Hold rating on Sanofi, with a price target of €85.00. The company’s shares closed yesterday at €81.90. According to ...

Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, ...

In this video, Brian S. Kim, MD, discusses the management of patients with severe chronic spontaneous urticaria.

According to TipRanks.com, Scala is a 5-star analyst with an average return of 10.6% and a 63.6% success rate. Scala covers the Healthcare sector, focusing on stocks such as Merck & Company, ...

So, the current treatment options for chronic spontaneous urticaria include antihistamines, which have always been used at ...

Piper Sandler starts Regeneron at overweight with $875 price target, citing Dupixent growth and pipeline catalysts. Read more ...

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of ...

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host diseaseRezurock is now approved in the EU for adults and children aged 12 ...

Despite hitting key goals across three late-stage studies, the drug, which targets the “OX40” ligand, raises safety and ...

Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is ...